Larimar Therapeutics, Inc. (LRMR)
Data as of , from SEC Form 4 filings.
See up to 3 months of LRMR. The 7-day demo opens the 1M and 3M ranges and puts LRMR on your watchlist.
Start 7-day demoLatest LRMR insider trades
About Larimar Therapeutics, Inc. (LRMR)
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
- BALA CYNWYD, PA
- 71
- 2020
- XNAS
LRMR Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 2 | 850,000 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
LRMR insider transactions (Form 4)
3121 Form 4 filings on record, the earliest from May 13, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
 John B. Harlow Jr. - Officer | Grant or award | Common Stock | 50,000 footnote F1 | $0.00 | - | |
| John B. Harlow Jr. - Officer | Grant or award | Stock Option (Right to Buy) | 800,000 | $0.00 | - | |
| ||||||
| Thomas Edward Hamilton | Open-market purchase | Common Stock | 50,000 | $3.34 footnote F1 | $167K | |
| ||||||
| James E. Flynn - Director | Grant or award | Stock Option (Right to Buy) | 55,150 footnote F1 | $0.00 | - | |
| ||||||
| Jonathan S. Leff | Grant or award | Stock Option (Right to Buy) | 55,150 footnote F1 | $0.00 | - | |
| ||||||
| Jeffrey W. Sherman | Grant or award | Stock Option (Right to Buy) | 55,150 | $0.00 | - | |
| Joseph Truitt | Grant or award | Stock Option (Right to Buy) | 55,150 | $0.00 | - | |
| Frank E. Thomas | Grant or award | Stock Option (Right to Buy) | 55,150 | $0.00 | - | |
| Thomas Edward Hamilton | Grant or award | Stock Option (Right to Buy) | 55,150 | $0.00 | - | |
| James E. Flynn - Director | Open-market purchase | Common Stock | 1,084,010 | $5.00 | $5.42M | |
| James E. Flynn - Director | Open-market purchase | Common Stock | 1,084,012 | $5.00 | $5.42M | |
| James E. Flynn - Director | Open-market purchase | Common Stock | 831,978 | $5.00 | $4.16M | |
| James E. Flynn - Director | Open-market purchase | Common Stock | 2,000,000 | $5.00 | $10.00M | |
| Thomas Edward Hamilton | Open-market purchase | Common Stock | 100,000 footnote F1 | $5.00 | $500K | |
| ||||||
| Frank E. Thomas | Open-market purchase | Common Stock | 5,000 footnote F1 | $5.00 | $25K | |
| ||||||
| Jeffrey W. Sherman | Open-market purchase | Common Stock | 5,000 footnote F1 | $5.00 | $25K | |
| ||||||
 Gopi Shankar - Officer | Grant or award | Common Stock | 25,637 footnote F1 | $0.00 | - | |
| Gopi Shankar - Officer | Grant or award | Stock Option (Right to Buy) | 153,822 | $0.00 | - | |
| ||||||
 Russell Clayton - Officer | Grant or award | Common Stock | 25,637 footnote F1 | $0.00 | - | |
| Russell Clayton - Officer | Grant or award | Stock Option (Right to Buy) | 153,822 | $0.00 | - | |
| ||||||
| Carole Ben-Maimon - Officer | Grant or award | Common Stock | 100,100 footnote F1 | $0.00 | - | |
| Carole Ben-Maimon - Officer | Grant or award | Stock Option (Right to Buy) | 600,600 | $0.00 | - | |
| ||||||
 Michael Celano - Officer | Grant or award | Common Stock | 37,604 footnote F1 | $0.00 | - | |
| Michael Celano - Officer | Grant or award | Stock Option (Right to Buy) | 225,622 | $0.00 | - | |
| ||||||
| James E. Flynn - Director | Open-market purchase | Common Stock | 3,387,529 | $3.20 | $10.84M | |
| James E. Flynn - Director | Open-market purchase | Common Stock | 3,387,539 | $3.20 | $10.84M | |
| James E. Flynn - Director | Open-market purchase | Common Stock | 2,599,932 | $3.20 | $8.32M | |
| Frank E. Thomas - Director | Grant or award | Stock Option (Right to Buy) | 19,000 | $0.00 | - | |
| Jeffrey W. Sherman - Director | Grant or award | Stock Option (Right to Buy) | 19,000 | $0.00 | - | |
| Jonathan S. Leff - Director | Grant or award | Stock Option (Right to Buy) | 19,000 | $0.00 | - | |
| James E. Flynn - Director | Grant or award | Stock Option (Right to Buy) | 19,000 | $0.00 | - | |
LRMR insider trading FAQ
What is the latest insider trade for LRMR?
Larimar Therapeutics, Inc. (LRMR) had 1 insider filing in the last 90 days, with the most recent on 2026-10-01. The full record for LRMR runs to 21 Form 4 filings, the earliest from 2025-05-13. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying LRMR stock?
No insider purchases of LRMR were filed in the last 90 days. 11 purchases are on record for this company.
How many insiders are selling LRMR stock?
No insider sales of LRMR were filed in the last 90 days.
Where can I see LRMR SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects LRMR Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - John B. Harlow Jr. view on EDGAR
- - Thomas Edward Hamilton view on EDGAR
- - James E. Flynn view on EDGAR
- - Jonathan S. Leff view on EDGAR
- - Jeffrey W. Sherman view on EDGAR
- - Joseph Truitt view on EDGAR
- - Frank E. Thomas view on EDGAR
- - Thomas Edward Hamilton view on EDGAR
- - James E. Flynn view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where LRMR's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow LRMR with a 7-day demo
- LRMR on your watchlist
- Every LRMR Form 4 filing on record
- Up to 3 months of LRMR price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
